Sun Pharmaceutical, Dr Reddy's line up new drugs amid price war

Arm themselves with speciality and complex drugs facing less competition

sun pharma
Photo: Reuters

To stave off pricing pressure in the US, Sun Pharmaceutical and Dr Reddy's Laboratories have built pipelines of drugs that face less competition and command better pricing power.  Mumbai-based Sun Pharma has already invested $600 million in seven speciality assets in dermatology, ophthalmology, central nervous system and oncology. Two drugs are already in the market, and the lead dermatology drug, MK-3222, should be launched in the first quarter of 2018-19. Speciality drugs are novel drugs for niche therapies needing more funds for development. Also unlike generic drugs ...